CD274 and non-small cell lung carcinoma: A Phase II clinical trial (NCT0287994) was conducted to specifically evaluate the efficacy of pembrolizumab (anti-PD-1 monoclonal antibody) in TKI-naïve EGFR-mutant advanced NSCLC patients whose tumors have high PD-L1 expression (49).